Literature summary for 1.4.3.4 extracted from

Lecht, S.; Haroutiunian, S.; Hoffman, A.; Lazarovici, P.
Rasagiline - a novel MAO B inhibitor in Parkinsons disease therapy (2007), Ther. Clin. Risk Manag., 3, 467-474.

Search for more literature for 1.4.3.4

Application

Application	Comment	Organism
medicine	the MAO B inhibitor rasagiline is initiated at 1 mg once-daily dosage as monotherap in early Parkinsons disease patients and at 0.51 mg once-daily as adjunctive to levodopa in advanced Parkinsons disease patients. Rasagiline treatment is not associated with cheese effect and up to 20 mg per day is well tolerated. In Parkinsons disease patients with hepatic impairment, rasagiline dosage should be carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and coadministration with certain antidepressants and opioids should be avoided. This drug provides an additional tool for Parkinsons disease therapy improvement in motor performance	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
rasagiline	i.e. N-propargyl-1-R-aminoindan. Irreversible MAO B inhibitor. Rasagiline is initiated at 1 mg once-daily dosage as monotherapy in early Parkinsons disease patients and at 0.5-1 mg once-daily as adjunctive to levodopa in advanced Parkinsons disease patients. Rasagiline treatment is not associated with cheese effect and up to 20 mg per day is well tolerated. In Parkinsons disease patients with hepatic impairment, rasagiline dosage should be carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and coadministration with certain antidepressants and opioids should be avoided. This drug provides an additional tool for Parkinsons disease therapy improvement in motor performance	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	P27338	-	-

Synonyms

Synonyms	Comment	Organism
MAO B	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)